Table III. Progresssion-Free Survival and Overall Survival in Patients with High-Grade Appendiceal Mucinous Carcinoma Peritonei Treated with HIPEC with or Without Perioperative Chemotherapy.
| HIPEC alone (n = 39) | Post-SC (n = 22) | Pre-SC (n = 37) | Both (n = 11) | |
|---|---|---|---|---|
| Progression-free survival | ||||
| 1-year % (SE) | 27 (7) | 63 (10) | 30 (8) | 55 (15) |
| 2-year % (SE) | 14 (6) | 24 (9) | 4 (4) | 9 (9) |
| Median (months) | 7.0 | 13.6 | 6.8 | 12.9 |
| P-value vs. post-SC | 0.03 | — | <0.01 | 0.24 |
| Overall survival | ||||
| 1-year % (SE) | 65 (8) | 90 (6) | 59 (8) | 73 (13) |
| 3-year % (SE) | 28 (8) | 53 (12) | 25 (10) | 18 (12) |
| Median (months) | 19.6 | 36.4 | 16.0 | 17.8 |
| P-value vs. post-SC | 0.14 | — | 0.07 | 0.17 |
HIPEC, hyperthermic intraperitoneal chemotherapy; Post-SC, post-operative systemic chemotherapy; Pre-SC, pre-operative systemic chemotherapy; SE, standard error.